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It has been shown previously  (1) that a linear relationship exists between
the quantity of serum and the quantity of influenza  A virus (2) neutralized.
This  relationship  was  established  on  the  basis  of  experiments  performed
with  the  serum  of ferrets  convalescent  from  experimental  influenza  and
the  serum  of  rabbits immunized  with  the  virus.  It  was  shown  that  by
means of this relationship it was possible  to calculate  the greatest quantity
of virus which  either rabbit or ferret antisera could neutralize  in the undi-
luted state.  It was  suggested that this fixed value, the neutralizing  capac-
ity, which was independent  of the quantity of virus used  in the neutraliza-
tion  test,  had an entirely  different  significance  than  the more  commonly
used  serum dilution end point or titer, which was a function of the quantity
of  virus  used.
In order  to  assess  accurately  the  significance  of  the  antibody  levels  of
the serum of normal human beings against influenza A virus, or the antibody
increases which  follow an attack of influenza  A  (2) in man, it was of impor-
tance to study the neutralization of influenza A virus by human serum in an
identical  manner  and  to  determine  whether  a  similar  linear  relationship
between  serum  and virus  neutralized  existed  under  these  conditions.
It  is  the  purpose  of  this  paper  to  report  the  results  of  quantitative
neutralization  tests carried  out with  two  strains of  influenza  A  virus and
an acute phase and  convalescent  serum obtained  from one individual  who
had influenza  A.
Material and Methods
Virus.-The PR8 strain  (3) and the  W.S. strain  (4)  of influenza  A virus were used.
Stock suspensions of infected mouse lungs were prepared and stored in a manner identical
with that previously described  (1).
Serum.-Acute phase serum was obtained from a patient with influenza A 4 days after
the  clinical  onset  of  the  disease.  This  patient  was  one  of  many who  suffered  from
influenza  A during  an  epidemic  which  occurred  in  1939,  studies  on which  have  been
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reported  previously  (5).  A  convalescent  serum  was  obtained  from  the  same  patient
26 days  after  onset.
Neutralization Tests.-Quantitative neutralization  tests  were  performed  exactly  as
described previously  (1).  Decimal dilutions of virus were  each tested against a number
of serial  serum dilutions.  Each test with  either strain  of virus and either  serum was
repeated  on three separate occasions.  Each mixture  of serum and virus was inoculated
intranasally  into a group of six lightly anesthetized mice.
Virus  Titrations.-Titrations of  the  infectiousness  of  the  virus  suspensions  were
performed  in  a manner identical with that described  previously  (1).  Each individual
neutralization  test  was  controlled  by  a titration  of the virus  done at  the same  time.
Groups of  six lightly anesthetized mice  were inoculated  intranasally with each dilution
of virus.
Calculation of End Points.-Both the virus titration end points  and the serum dilu-
tion end points were calculated by the 50 per cent end point method of Reed and Muench
(6).  Since  the  50  per cent  mortality  end point  has been found to be somewhat  more
accurate  than any of the other end points which  can be  calculated  in such  tests with
influenza A virus, this end point has been used throughout the present investigation.
EXPERIMENTAL
Decimal dilutions of the PR8 strain of influenza A virus were each tested
against  a number  of  serial dilutions of  both  the acute phase and  the con-
valescent  sera.  Each  of  these  two  sera was  used  in three  separate  tests.
The results obtained  in one test with the convalescent  serum  are shown in
Table  I.  It  will  be  noted  that the  survival  or  death  of  mice  in groups
inoculated with the various mixtures of virus and serum show quite clearly
that as the quantity of virus  was decreased  decimally,  the serum  dilution
end  points  did  not  increase  proportionately  but  instead  increased  by
approximately  fivefold.
The mean  50 per  cent mortality dilution end points obtained  in  the  six
neutralization  tests with the acute phase and the convalescent  sera against
varying  amounts  of the  PR8  strain are presented  in Table  II.  It  will be
observed that the neutralizing  titers of both the acute  phase and the con-
valescent  sera  were  increased  by  approximately  5  times  as  the  quantity
of  virus  against  which  they  were  tested  was  decreased  by  10  times.  It
will also  be noted that the increased  neutralizing titer of  the convalescent
serum as compared with the titer of the acute phase serum was practically
independent of the quantity of virus used and  remained  constant at each
virus dilution.
The  results  obtained  in  all of the neutralization  tests  with these  two  sera and  the
PR8 strain are presented graphically  in Fig.  1.  The logarithm  of each serum dilution
end point has been plotted against  the logarithm of the quantity  of  virus neutralized.
It will be  observed that when the  quantity  of virus  used in each  test was  taken  into
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account,  the three  sets  of end  points obtained  with  each  serum  fell  reasonably  close
together.  Straight lines which appeared  to fit these end points well have  been drawn
through them.  These lines were  purposely  drawn with a slope identical to that previ-
ously determined in experiments on the linear relationship between serum and virus with
ferret  and rabbit antisera  (1).  It  is apparent  that  there  does  not appear  to  be  any
TABLE  I
Results of Neutralization Tests with Decreasing Quantities  of the PR? Strain of Influenza A
Virus and Convalescent Human Serum
Virus  No  Serum dilution  Virus
VV  ~  ~  ___  ___irus  No  neutral-
dilution  serum  ne
dilution  1:5  1:25  1:125  1:625  1:3,125  1:15,625  1:78,125  1iEd
10-1  - 5S  1D  6D  6D  6D  - - - 10.6
10-2  - 6S  6S  6D  6D  6D  - - 10
.s
10-8  - - 6S  6S  6D  6D  6D  - 10.6
10
-4 6D  - - 6S  6S  6D  6D  6D  102.6
10-n  6D  - - - 6S  6S  6D  6D'  10'.6
10--  6D  - - -
10o-  5S 1D
10s 6S
S  =  mouse survived observation period of 11 days.
D  = mouse died with ++++ pulmonary consolidation.
TABLE  II
Mean 50 Per Cent Mortality  Dilution  End Points of Acute Phase and Convalescent Human
Sera against the PR8 Strain of Influenza A  Virus
Raeds  Mean 50 per cent mortality serum dilution
end point
Increase in titer




10-2  104-.  1:4  1:35  8.7X
10-  oa10  1:21  1:186  8.8X
104 10 ' o26  1:129  1:742  5.8X
lo- s o l .6  1:602  1:5120  8.5X
systematic  deviation  of  the  experimental  end  points  from  either  of  the  two  straight
lines.  Twelve  end  points found  with  the acute phase serum  and the PR8  strain are
shown in Fig. 1.  These end points had, on the X axis, a mean deviation from neutraliza-
tion line (II) of log :0.19.  The two maximum deviations from this line were log 40.35.
Fifteen end points determined with  the convalescent  serum and the PR8 strain are also
shown.  These end points had, on the same axis, a mean deviation from neutralization
line  (I)  of log  -0.11.  The  two  maximum  deviations  from  this line  were log  40.22.
The  line  X  has  been inserted  in  Fig.  1 to  show  graphically  the  difference  between
the so called standard neutralizing titers (7)  of the acute phase and the convalescent sera.
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The length of this line, which  corresponds  to log  -2.37 minus log  -1.47 or log  -0.90,
indicates  that the  convalescent  serum had  a standard titer 7.9 times greater  than that
of the acute phase  serum.  The  line  Y1  also has been inserted in Fig. 1 to demonstrate
graphically  the  difference  between  the neutralizing  capacities  of these two  sera.  The
length  of this  line, which  corresponds  to log 6.91  minus log 5.61  or log  1.30,  indicates
that the convalescent  serum has a virus-neutralizing capacity  20 times greater than that
of the acute phase serum.
Decimal  dilutions of  the W.S.  strain were each  tested against  a number
of serial dilutions of both the acute phase and the convalescent sera.  Three
separate  neutralization  tests  were  run  with  this  strain  of  virus  and  each
Log quantity  erum  Log quantity  eepum
FIG.  1  FIG.  2
serum.  The mean  50 per cent mortality dilution end points obtained with
these two sera and the W.S.  strain are shown in Table III.  It will be seen
again  that the titers of both  sera were increased  by approximately  5 times
as the quantity of  virus against  which  they were tested  was decreased  by
10 times.  Moreover,  it will be noted that the increase in titer of the con-
valescent serum  as compared  with that of the acute phase serum was  rela-
tively  constant  and  was  independent  of  the quantity  of  virus  used.
The  results  of all  the  tests  with  the  acute  phase  and  convalescent  serum  and the
W.S.  strain  are presented  in  Fig.  2.  The logarithm of  each  serum dilution end point
has been plotted against  the logarithm of the  quantity of virus neutralized.  It  will be
observed that the three sets of end points for each serum fell reasonably  close together.
Straight lines which appear to fit these experimental points well have been drawn through
them.  These lines were drawn purposely with slopes identical to those shown in Fig. 1.
It  seems  evident  that  there  is  no  systematic  deviation  of  the  end  points  from these
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lines except  in the three  instances in which less than five 50 per cent mortality  doses of
virus  were  neutralized.  Thirteen  end points obtained  with the acute phase serum and
the W.S. strain are shown in Fig. 2.  These end points had, on the X axis, a mean devia-
tion from neutralization  line (II) of log  i0.11.  The two maximum deviations observed
were log  0.20.  Sixteen end points determined with  the convalescent  serum and the
W.S. strain are also shown.  These end points had, on the same axis, a mean deviation
from the neutralization line  (I) of log ~0.12.  The two maximum deviations found were
log  40.32.  The line  Xi  has  been drawn in Fig. 2 to demonstrate graphically  the in-
crease in standard  neutralizing  titer of the  convalescent  serum.  It  will  be  observed
that this increase corresponded  to log 0.91,  which  represented an arithmetic increase  in
titer of 8.1  times.  The line  Y1  has  been drawn in Fig. 2 to show  graphically the  in-
crease  in  virus-neutralizing  capacity  of  the  convalescent  serum.  This  increase  cor-
TABLE III
Mean 50 Per Cent Mortality Dilution End Points  of Acute Phase and Convalescent Human
Sera against the W.S. Strain of Influenza A  Virus
Virus  Mean  50  per cent  mortality serum dilution end point
Increase in titer
etDilution  otai
5 Acute  phase  Convalescent
tog
10-'  10 5 . _  1:11-
10-2  4.5  1:11  1:87  7.9X
10
-- 10
a . 6  1:59  1:490  8.3X
10
4 102.65  1:302  1:2510  8.3X
10o
-6 10
t . 1:1120  1:9550  8.5X
responded to log 1.31,  which represented an arithmetic increase in neutralizing capacity
of  20 times.
DISCUSSION
It  is  quite  obvious that  serum  dilution  end points  or titers  are  strictly
dependent upon the amount of virus used in a test.  If the antibody levels
of multiple serum specimens from one individual or from different  persons
are  to  be  evaluated  accurately,  it  is  important  that  the  sera  be  tested
against  equal  amounts  of virus.  Frequently  it  is  difficult  to  accomplish
this since it is manifestly impractical to include more than a limited number
of sera in one test.  In certain previous  investigations  (5,  7)  with human
sera  this  difficulty  was  circumvented  by  the  determination  of  so  called
standard  neutralization  titers.  The quantity  of virus,  10  .5 fifty per  cent
mortality doses,  used in determining the standard titers was so large, how-
ever, that approximately 40 per cent of human sera failed to neutralize it  (7).
On the other hand, when  101.5 fifty per cent mortality  doses of virus were
used, it was found that at least 95 per cent of normal human sera possessed
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a  definite  capacity  to  neutralize  influenza  A  virus,  whereas  the  sera  of
normal experimental animals did not.
Not only  did  the neutralization  titer  of  a given  human  serum  depend
upon the amount  of virus used in a test, but also, as has been shown,  sera
became  progressively  less  and  less  efficient  in  their  abilities  to neutralize
the  virus as  they  were  diluted  more  and more.  When  experimental  end
points  obtained  in  neutralization  tests  were  plotted  logarithmically,  it
became  apparent  that a  linear relationship  existed  between  the  quantity
of human serum used and the quantity of virus neutralized.  This relation-
ship  seemed to  be identical  with that found previously  (1) in experiments
with ferret and  rabbit antisera.  Moreover,  the relationship  remained  the
same in tests with two antigenically different  (8)  strains of influenza A virus,
By  means  of this  relationship  it  is possible  to calculate  the  maximum  quantity  of
virus  which a particular  serum  can neutralize.  It  has been shown  (1) that  the whole
course  of the neutralization  of  influenza A virus  by either ferret or rabbit antisera  can
be expressed  by  the  equation
y  =  bx'
in which y is the quantity of virus neutralized,  b the intercept  on the y axis, x the  serum
dilution  end point,  and a an  experimental  constant which  has been  found to be  1.44.
This equation and the constant  1.44 also can be applied to human sera.  It  is  apparent
that the  neutralizing capacity,  b, of  a serum can be estimated most  accurately  when  a
number  of serum dilution  end points are determined  against various  amounts  of virus.
A straight line, with the proper  slope, drawn through these points intercepts  the y  axis
at a point which  indicates  the greatest quantity  of virus  the serum can  neutralize.  It
is obviously impractical  to determine a number of dilution  end points with every  serum
since the number of mice required would be very large.  However, under  the conditions
of  these  experiments,  the  accuracy  of individual  dilution  end points was  found  to  be
sufficiently  high to permit the calculation  of the neutralizing  capacity of a serum from a
single end point, providing the quantity of virus neutralized was also known.  By means
of the equation
log b =  log  y - (a log x)
the neutralizing capacity of a given serum can be determined directly from the logarithm
of  the  serum dilution  end point.  It  is of importance  to point  out  that x,  the  serum
dilution end point, is a fractional  quantity and,  therefore, that log x is always negative.
The  neutralizing  capacity  of  a  serum  appears  to  be  a  fixed  quantity
which  is independent  of  the  amount  of  virus  used  in  the  neutralization
test.  It serves to characterize  definitely the antibody level of a serum and
circumvents the numerous practical and theoretical  difficulties  which  arise
from the  use of neutralization  titers.
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SUGMARY
A linear  relationship  exists between  the quantity  of human  serum  used
and  the  quantity  of  influenza  A  virus  neutralized.  By  means  of  this
relationship  it  is  possible  to  determine  the  maximum  quantity  of  virus
which a given human serum can neutralize.  This quantity, the neutralizing
capacity,  is a fixed value and, unlike the serum dilution end point, is inde-
pendent of the amount of virus used in  the neutralization  test.
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